Education
About Us
Working with TipRanks
Follow Us
Talphera, Inc. (TLPH)
:TLPH
TLPH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.45 - $1.27
Previous CloseN/A
Volume42.81K
Average Volume (3M)49.99K
Market Cap
$7.88M
Enterprise Value$4.89M
Total Cash (Recent Filing)$3.06M
Total Debt (Recent Filing)$12.01M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
May 19, 2025EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding17,098,345
10 Day Avg. Volume48,383
30 Day Avg. Volume49,990
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)38.46
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market Cap0.62
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.00
Enterprise Value/Ebitda-0.32
Forecast
1Y Price Target
$4.33Price Target Upside802.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Talphera News
PremiumCompany Announcements
Talphera, Inc. Earnings Call: Progress Amid Challenges
PremiumCompany Announcements
Talphera Reports 2024 Financial Results and Study Update
---
Bulls Say, Bears Say
Bulls Say
Product PotentialThere is a positive outlook on Niyad (nafamostat) and its potential as a regional anticoagulant for the extracorporeal circuit (ECC).
Regulatory ApprovalTalphera reached an agreement with the FDA to reduce the number of patients for the Phase 3 NEPHRO CRRT study to 70 patients, which should allow the trial to complete faster and reduce potential total cash expenses.
Bears Say
Enrollment ChallengesPatient enrollment for the NEPHRO CRRT study has been sluggish, with only six patients enrolled since November 2024.
Regulatory RisksKey risks to the rating and price target include failed or equivocal trial results and failure to secure FDA approval for Niyad.
---
Ownership Overview
15.46% Insiders
2.30% Mutual Funds
19.39% Other Institutional Investors
61.44% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
TLPH FAQ
What was Talphera, Inc.’s price range in the past 12 months?
Talphera, Inc. lowest stock price was $0.45 and its highest was $1.27 in the past 12 months.
What is Talphera, Inc.’s market cap?
Talphera, Inc.’s market cap is $7.88M.
When is Talphera, Inc.’s upcoming earnings report date?
Talphera, Inc.’s upcoming earnings report date is May 19, 2025 which is in 30 days.
How were Talphera, Inc.’s earnings last quarter?
Talphera, Inc. released its earnings results on Mar 31, 2025. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.143 by $0.073.
Is Talphera, Inc. overvalued?
According to Wall Street analysts Talphera, Inc.’s price is currently Undervalued.
Does Talphera, Inc. pay dividends?
Talphera, Inc. does not currently pay dividends.
What is Talphera, Inc.’s EPS estimate?
Talphera, Inc.’s EPS estimate is -0.17.
How many shares outstanding does Talphera, Inc. have?
Talphera, Inc. has 17,098,345 shares outstanding.
What happened to Talphera, Inc.’s price movement after its last earnings report?
Talphera, Inc. reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.143. Following the earnings report the stock price went up 6%.
Which hedge fund is a major shareholder of Talphera, Inc.?
Currently, no hedge funds are holding shares in TLPH
---
Company Description
Talphera, Inc.
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. Talphera, Inc. was incorporated in 2005 and is headquartered in San Mateo, California.
---
TLPH Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call detailed significant progress, including FDA approvals and financial backing, improving the outlook for the NEPHRO CRRT study. However, challenges with initial study sites and uncertainty regarding enrollment timelines were noted.Read More>---
TLPH Stock 12 Month Forecast
Average Price Target
$4.33
▲(802.08% Upside)
Technical Analysis
Relmada Therapeutics
―
Immuron
―
MSP Recovery
―
Intelligent Bio Solutions
―
Neuphoria Therapeutics
―
Best Analysts Covering TLPH
1 Year
1 Year Success Rate
4/15 ratings generated profit
1 Year Average Return
-15.09%
reiterated a buy rating 18 days ago
Copying Ed Arce's trades and holding each position for 1 Year would result in 26.67% of your transactions generating a profit, with an average return of -15.09% per trade.
---